Glycemic control of newly-diagnosed type 2 diabetes with different baseline body mass index under the standardized metabolic disease management model

Q4 Medicine 中华内分泌代谢杂志 Pub Date : 2019-12-25 DOI:10.3760/CMA.J.ISSN.1000-6699.2019.12.006

Jingjing Huang, Yuhang Ma, Mengyu Lai, Jiaying Yang, Xiaohui Wei, Aifang Zhang, Liping Gu, Yufan Wang

{"title":"Glycemic control of newly-diagnosed type 2 diabetes with different baseline body mass index under the standardized metabolic disease management model","authors":"Jingjing Huang, Yuhang Ma, Mengyu Lai, Jiaying Yang, Xiaohui Wei, Aifang Zhang, Liping Gu, Yufan Wang","doi":"10.3760/CMA.J.ISSN.1000-6699.2019.12.006","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the glycemic control of newly-diagnosed type 2 diabetes with different levels of baseline body mass index (BMI) after 6 months treatment under the standardized metabolic disease management model. \n \n \nMethods \n(1) 163 patients of newly-diagnosed type 2 diabetes were divided into normal weight (BMI 18.5-23.9 kg/m2), overweight (BMI 24.0-27.9 kg/m2), and obese (BMI≥28 kg/m2) groups according to baseline BMI, the blood glucose and lipids levels were compared among 3 groups. (2) The blood glucose levels were compared among 3 groups after 6 months of standardized management. (3) The overweight and obese patients were divided into group weight loss≥5% and group weight loss<5% or weight gain in 6 months. The blood glucose levels were compared. \n \n \nResults \n(1) At baseline, overweight and obese groups had higher homeostasis model assessment for insulin resistance and lower high density lipoprotein-cholesterol compared with normal weight group. (2) After 6 months of treatment, HbA1C and HbA1C reduction showed no difference among 3 groups (normal, overweight and obese) after adjusted by baseline HbA1C. The rate of HbA1C 0.05). (3) After 6 months of treatment, 32.28% overweight and obese patients lost weight by ≥ 5%, while HbA1Cand HbA1Creduction showed no difference between 2 groups (weight loss≥5% and weight gain or weight loss 0.05). Group weight loss≥5% had better glucose control (92.68% vs 77.91%, P<0.05). \n \n \nConclusions \nAs BMI increased, insulin resistance and lipid disorders were more serious in newly-diagnosed type 2 diabetes. After 6 months of standardized metabolic management, newly-diagnosed type 2 diabetes with different baseline BMI and weight changes both achieved good glycemic control. In addition, patients losing weight equal to or more than 5% achieved higher attainment of HbA1C targets. \n \n \nKey words: \nNewly-diagnosed type 2 diabetes; Body mass index; HbA1C; Weight changes","PeriodicalId":10120,"journal":{"name":"中华内分泌代谢杂志","volume":"35 1","pages":"1025-1030"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华内分泌代谢杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1000-6699.2019.12.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To explore the glycemic control of newly-diagnosed type 2 diabetes with different levels of baseline body mass index (BMI) after 6 months treatment under the standardized metabolic disease management model. Methods (1) 163 patients of newly-diagnosed type 2 diabetes were divided into normal weight (BMI 18.5-23.9 kg/m2), overweight (BMI 24.0-27.9 kg/m2), and obese (BMI≥28 kg/m2) groups according to baseline BMI, the blood glucose and lipids levels were compared among 3 groups. (2) The blood glucose levels were compared among 3 groups after 6 months of standardized management. (3) The overweight and obese patients were divided into group weight loss≥5% and group weight loss<5% or weight gain in 6 months. The blood glucose levels were compared. Results (1) At baseline, overweight and obese groups had higher homeostasis model assessment for insulin resistance and lower high density lipoprotein-cholesterol compared with normal weight group. (2) After 6 months of treatment, HbA1C and HbA1C reduction showed no difference among 3 groups (normal, overweight and obese) after adjusted by baseline HbA1C. The rate of HbA1C 0.05). (3) After 6 months of treatment, 32.28% overweight and obese patients lost weight by ≥ 5%, while HbA1Cand HbA1Creduction showed no difference between 2 groups (weight loss≥5% and weight gain or weight loss 0.05). Group weight loss≥5% had better glucose control (92.68% vs 77.91%, P<0.05). Conclusions As BMI increased, insulin resistance and lipid disorders were more serious in newly-diagnosed type 2 diabetes. After 6 months of standardized metabolic management, newly-diagnosed type 2 diabetes with different baseline BMI and weight changes both achieved good glycemic control. In addition, patients losing weight equal to or more than 5% achieved higher attainment of HbA1C targets. Key words: Newly-diagnosed type 2 diabetes; Body mass index; HbA1C; Weight changes

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

标准化代谢性疾病管理模式下不同基线体重指数新诊断2型糖尿病患者的血糖控制

目的探讨在标准化代谢疾病管理模式下，不同基线体重指数（BMI）水平的新诊断2型糖尿病患者在治疗6个月后的血糖控制。方法（1）将163例新诊断的2型糖尿病患者按基线BMI分为正常体重组（BMI 18.5-23.9 kg/m2）、超重组（BMI 24.0-27.9 kg/m2）和肥胖组（BMI≥28 kg/m2），比较3组患者的血糖和血脂水平。（2）经过6个月的标准化管理，比较了3组患者的血糖水平。（3）超重和肥胖患者分为体重减轻≥5%组和体重减轻<5%或6个月内体重增加组。比较血糖水平。结果（1）与正常体重组相比，在基线时，超重和肥胖组的胰岛素抵抗稳态模型评估更高，高密度脂蛋白胆固醇更低。（2）治疗6个月后，经基线HbA1C调整后，3组（正常、超重和肥胖）的HbA1C和HbA1C降低没有差异。（3）治疗6个月后，32.28%的超重和肥胖患者体重减轻≥5%，而HbA1C和HbA1Credition在两组之间没有差异（体重减轻≥5%和体重增加或减轻0.05），胰岛素抵抗和脂质紊乱在新诊断的2型糖尿病中更为严重。经过6个月的标准化代谢管理，具有不同基线BMI和体重变化的新诊断的2型糖尿病都实现了良好的血糖控制。此外，体重减轻等于或超过5%的患者实现了更高的HbA1C目标。关键词：新诊断2型糖尿病；体重指数；HbA1C；重量变化

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中华内分泌代谢杂志 Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

0.60

自引率

0.00%

发文量

7243

期刊介绍： The Chinese Journal of Endocrinology and Metabolism was founded in July 1985. It is a senior academic journal in the field of endocrinology and metabolism sponsored by the Chinese Medical Association. The journal aims to be the "Chinese broadcaster of new knowledge on endocrinology and metabolism worldwide". It reports leading scientific research results and clinical diagnosis and treatment experience in endocrinology and metabolism and related fields, as well as basic theoretical research that has a guiding role in endocrinology and metabolism clinics and is closely integrated with clinics. The journal is a core journal of Chinese science and technology (a statistical source journal of Chinese science and technology papers), and is included in Chinese and foreign statistical source journal databases such as the Chinese Science and Technology Papers and Citation Database, Chemical Abstracts, and Scopus.